Biocon result and the announcement , cleverly placed, the sale of a new breast cancer drug in India, will see some sharp movement in this counter 460 call seems attractive, as do futures.The stock is really in uncharted territory but the risk to reward makes it worth going long.The stop loss would be 428 on spot.Which is unlikely to be hit at anytime soon.As a long term investment BIOCON is attractive we can see 600 to 700 levels in 4 to 5 months.